Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia

Seok Jin Kim, Jeeyong Kim, Yunjung Cho, Bo Kyoung Seo, Byung Soo Kim

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1-4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.

Original languageEnglish
Pages (from-to)382-384
Number of pages3
JournalJapanese Journal of Clinical Oncology
Volume37
Issue number5
DOIs
Publication statusPublished - 2007 May 1

Fingerprint

Plasma Cell Leukemia
Combination Drug Therapy
Cyclophosphamide
Dexamethasone
Intravenous Infusions
Plasma Cells
Peripheral Blood Stem Cell Transplantation
Immunoglobulin D
Drug Therapy
Thalidomide
Therapeutics
Multiple Myeloma
Doxorubicin
Bone Marrow
Bortezomib

Keywords

  • Bortezomib
  • Cyclophosphamide
  • Multiple myeloma
  • Plasma cell leukemia

ASJC Scopus subject areas

  • Oncology

Cite this

@article{cdb725a7c2fd4158befb5206bf03e7db,
title = "Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia",
abstract = "Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1-4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.",
keywords = "Bortezomib, Cyclophosphamide, Multiple myeloma, Plasma cell leukemia",
author = "Kim, {Seok Jin} and Jeeyong Kim and Yunjung Cho and Seo, {Bo Kyoung} and Kim, {Byung Soo}",
year = "2007",
month = "5",
day = "1",
doi = "10.1093/jjco/hym037",
language = "English",
volume = "37",
pages = "382--384",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia

AU - Kim, Seok Jin

AU - Kim, Jeeyong

AU - Cho, Yunjung

AU - Seo, Bo Kyoung

AU - Kim, Byung Soo

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1-4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.

AB - Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1-4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.

KW - Bortezomib

KW - Cyclophosphamide

KW - Multiple myeloma

KW - Plasma cell leukemia

UR - http://www.scopus.com/inward/record.url?scp=34547869650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547869650&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym037

DO - 10.1093/jjco/hym037

M3 - Article

C2 - 17538191

AN - SCOPUS:34547869650

VL - 37

SP - 382

EP - 384

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

ER -